Cumberland Pharmaceuticals Inc. filings document a specialty pharmaceutical issuer with branded prescription products and clinical-development programs. The company's 8-K reports cover operating and financial results, FDA and clinical regulatory updates, material agreements, credit-facility amendments, capital-structure disclosures and other material events tied to its pharmaceutical portfolio.
Proxy materials and annual-meeting reports disclose board elections, auditor ratification, advisory compensation votes, executive compensation, beneficial ownership, corporate governance and shareholder proposal procedures. Financing-related filings describe revolving credit obligations, borrowing covenants, collateral arrangements and related debt disclosures.
Cumberland Pharmaceuticals Inc. insider A.J. Kazimi has filed a Schedule 13G reporting a significant ownership position in the company’s common stock. Kazimi beneficially owns 5,701,155 shares of Cumberland common stock, representing 38.07% of the outstanding class.
All of these shares are reported with sole voting and sole dispositive power, meaning Kazimi alone can vote and decide whether to sell or hold them. The filing confirms that no other person is identified as sharing voting or investment control over this ownership stake.
Cumberland Pharmaceuticals Inc. reported that the U.S. Food and Drug Administration has granted Fast Track Designation for its novel oral therapy targeting a fatal form of heart disease in patients with Duchenne muscular dystrophy (DMD). This status is intended to speed the development and review of treatments for serious conditions with unmet medical needs. Cumberland furnished a press release with additional details as an exhibit to this report.
Cumberland Pharmaceuticals director Caroline Young reported a series of small open‑market purchases of the company’s common stock in December 2025 under a pre-arranged Rule 10b5-1 trading plan. The filing shows daily acquisitions ranging from $2.24 to $4.32 per share between 12/01/2025 and 12/31/2025, each coded as transaction type “L.”
After the final reported purchase on 12/31/2025 at $3.91 per share, Young beneficially owned 33,309 shares of Cumberland common stock in direct form. A footnote explains that the purchases occurred automatically under a Rule 10b5-1 plan adopted on November 14, 2024, indicating these trades were scheduled in advance.
Cumberland Pharmaceuticals director Kenneth J. Krogulski reported a series of small open-market purchases of the company’s common stock in December 2025. The transactions, coded “L,” were executed under a Rule 10b5-1 trading plan that he adopted on November 14, 2024. Individual daily purchases ranged from dozens of shares at prices in the low single digits per share. The most recent reported transaction was on December 31, 2025, when he bought 62 shares at $3.91 each, bringing his directly held stake to 296,538 common shares following that trade.
Cumberland Pharmaceuticals Inc. entered into an amendment to its revolving credit arrangements with Pinnacle Bank. The amendment keeps the aggregate principal funding available at up to $25 million, with $15 million currently available for borrowing and the right for Cumberland to request an additional $10 million. The revolving line continues to be secured by substantially all of the company’s assets.
The facility includes a quarterly-tested Minimum Fixed Charge Coverage Ratio and Borrowing Base Requirements. Borrowings will bear interest at Benchmark Term SOFR plus 2.75%. The amendment also extends the credit facility’s maturity to October 1, 2027, giving Cumberland a longer-dated source of revolving liquidity.
Cumberland Pharmaceuticals (CPIX) filed its Q3 2025 report, showing quarterly net revenue of $8.29M versus $9.09M a year ago and a net loss of $1.95M. For the first nine months, revenue rose to $30.84M from $27.43M as growth in Sancuso and Vibativ offset weaker Kristalose.
Sancuso delivered $3.24M in Q3 sales (up year over year) and Vibativ $2.60M, while Kristalose fell to $1.18M amid authorized‑generic shipment delays and higher generic substitution. Cost of products sold was $0.99M, supporting strong gross margin.
Operating cash flow turned positive at $4.93M year‑to‑date, aided by working capital, while cash ended at $15.20M. Debt on the revolving credit facility declined to $5.24M. The company issued 1,000,000 shares via ATM for proceeds of about $5.5M. Shares outstanding were 14,956,627 as of November 5, 2025.
After quarter end, Cumberland and RedHill formed a joint company to co‑commercialize Talicia in the U.S., with Cumberland committing $4M over two years and recording U.S. product sales under an equal net‑revenue share.
Cumberland Pharmaceuticals Inc. filed a current report to furnish a press release dated November 4, 2025. The press release provides a company update and the financial results for the three and nine months ended September 30, 2025. The information is furnished under Item 2.02 regarding results of operations and financial condition and is not deemed filed for liability purposes under Section 18 of the Exchange Act unless later specifically incorporated by reference.
Cumberland Pharmaceuticals (CPIX) — insider share acquisitions reported. Director Caroline Young disclosed a series of automatic purchases executed under a Rule 10b5-1 trading plan.
The filing lists acquisitions of 6 shares on multiple trading days from October 1–31, 2025, at prices ranging from $3.14 to $3.63. Following the final reported transaction on October 31, 2025, the director beneficially owned 33,168 shares, held directly. The transactions were made pursuant to a 10b5-1 plan adopted on November 14, 2024.
Cumberland Pharmaceuticals (CPIX) director James Jones reported automatic open‑market purchases under a Rule 10b5‑1 trading plan. The filings show purchases of 13 shares on each trading day from October 1–31, 2025, at prices ranging from $3.14 to $3.63. Following these transactions, Jones beneficially owns 44,491 shares, held direct.
The Rule 10b5‑1 plan was adopted on November 14, 2024. No derivative securities were reported.
Cumberland Pharmaceuticals (CPIX) reported insider acquisitions by Chairman & CEO A.J. Kazimi on a Form 4. The filing lists a series of 13-share purchases on multiple days from 10/01/2025 through 10/31/2025, executed under a Rule 10b5-1 trading plan.
Reported prices ranged from $3.14 to $3.63 per share across the period. Following the latest transaction, Kazimi’s direct beneficial ownership is 5,700,583 shares.